stockrow
Friday 6 November 2026
Export BEAM’s income statement to Excel — free account
Beam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
26.32
0.45
+1.74%
Follow BEAM
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (11.29%) | (8.18%) | (5.77%) | (8.11%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 3 | 3 | 4 | |
| (8.40%) | (6.23%) | (4.48%) | (6.19%) | ||
ROIC |
(2,676.86%) | (1,599.30%) | (438.41%) | 0.00% | |
Return on Tangible Assets |
(10.04%) | (7.24%) | (5.10%) | (6.27%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.80) | (3.57) | (3.72) | (3.64) | |
Free Cash Flow |
(398.24) | (372.77) | (383.84) | (360.05) | |
Capital Expenditures |
(9.59) | (13.39) | (14.11) | (14.95) | |
| Other line items | |||||
Cash ROIC |
(18.99%) | (16.06%) | (15.50%) | (14.50%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
278.91% | 261.91% | 253.23% | 293.12% | |
Selling, General and Administrative Expense of Revenue |
88.77% | 80.36% | 73.35% | 81.45% | |
Share Based Compensation of Revenue |
52.73% | 52.24% | 52.80% | 67.44% | |
Operating CF/Net income |
3.59 | 4.15 | 5.60 | 4.31 | |
Depreciation/Fixed assets |
0.12 | 0.10 | 0.07 | 0.06 | |
Capex/Depreciation |
(0.88) | (1.41) | (1.87) | (2.36) | |
Revenue per Share |
1.40 | 1.50 | 1.59 | 1.41 | |
Operating CF per Share |
(3.71) | (3.44) | (3.58) | (3.49) | |
Capex per Share |
(0.09) | (0.13) | (0.14) | (0.15) | |
Capex to Sales |
0.07 | 0.09 | 0.09 | 0.11 |
Columns are period end dates · fundamentals updated 5 Nov 2026